The US Preventive Services Task Force recommends against initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) in adults 60 years or older. The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. This recommendation replaces the 2016 recommendation. The update is based on a systematic review on the effect of aspirin use on CVD and colorectal cancer and a microsimulation modeling study to assess the net balance of benefits and harms. Both CVD and bleeding risk increase with age. The benefits of initiating aspirin use are greater with higher CVD risk but become smaller with aging. Source: https://jamanetwork.com/
A secondary MRI analysis of the US POINTER randomized clinical trial found that a structured…
Dementia risk factors vary substantially across countries, but they frequently cluster together in similar patterns…
A systematic review and network meta-analysis of 262 randomized trials involving 99,791 participants found that…
Approximately 21% of patients with phenotypically mild hypertrophic cardiomyopathy (HCM) experienced major adverse cardiovascular events…
A Danish randomized crossover trial found that a single session of high-intensity interval exercise (HIIE)…
Baseline use of proton pump inhibitors (PPIs) and, to a lesser extent, antibiotics was associated…
This website uses cookies.